Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

OraSure Technologies Inc (OSUR) Com Stk Npv

Sell:$7.89 Buy:$7.90 Change: $0.08 (1.00%)
NASDAQ:0.40%
Market closed |  Prices as at close on 9 December 2019 | Switch to live prices |
Sell:$7.89
Buy:$7.90
Change: $0.08 (1.00%)
Market closed |  Prices as at close on 9 December 2019 | Switch to live prices |
Sell:$7.89
Buy:$7.90
Change: $0.08 (1.00%)
Market closed |  Prices as at close on 9 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing.

Contact details

Address:
150 WEBSTER ST
BETHLEHEM
18015
United States
Telephone:
+1 (503) 6416115
Website:
www.orasure.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OSUR
ISIN:
US68554V1089
Market cap:
$491.96 million
Shares in issue:
61.73 million
Sector:
Health Care Supplies
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Celano
    Independent Chairman of the Board
  • Stephen Tang
    President, Chief Executive Officer, Director
  • Brian Smith
    Vice Chairman of the Board, Executive Vice President - Innovation
  • Roberto Cuca
    Chief Financial Officer
  • Kathleen Weber
    Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG
  • Anthony Zezzo
    Executive Vice President, Business Unit Leader, Infectious Disease
  • Michael Reed
    Senior Vice President - Research and Development, Chief Scientific Officer
  • Jack Jerrett
    Senior Vice President, General Counsel, Secretary
  • Michele Miller
    Vice President - Finance, Controller, Assistant Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.